Literature DB >> 21478114

Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes.

Mirosława Püsküllüoglu1, Ewa Lukasiewicz, Katarzyna Miekus, Danuta Jarocha, Marcin Majka.   

Abstract

Rhabdomyosarcoma (RMS) represents the most common sarcoma of soft tissue among children. Two main RMS subtypes are alveolar (ARMS) and embryonal (ERMS). The major goal of this study was to find differentially expressed genes between RMS subtypes that could explain higher metastatic potential in ARMS and would be useful for the differential diagnosis. Using RQ-PCR analysis we compared expression of Snail1 and Snail-related genes among 7 ARMS and 8 ERMS patients' samples obtained from the primary tumors and among 2 alveolar and 2 embryonal cell lines. Our results show that Snail1 is highly expressed both in ARMS patients' samples and the alveolar cell lines. We also found that the expression of E-Cadherin was downregulated and the expression of Matrix Metalloproteinases 2 and 9 (MMP-2 and MMP-9) was upregulated in ARMS. We assume that, as in many tumors, also in RMS Snail1 acts as a regulator for pathways known for their role in cells' metastasis and that Snail1 activity results in increased MMPs and decreased E-Cadherin expression. Our findings may explain higher ARMS aggressiveness. Moreover, we suggest that further studies should be performed to verify if Snail1 can be considered as a potential target for ARMS therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21478114     DOI: 10.2478/v10042-010-0046-7

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  7 in total

1.  Differential remodeling of cadherins and intermediate cytoskeletal filaments influence microenvironment of solid and ascitic sarcoma.

Authors:  Malay Chaklader; Ankita Pan; Aditya Law; Sukalpa Chattopadhayay; Ritam Chatterjee; Sujata Law
Journal:  Mol Cell Biochem       Date:  2013-07-17       Impact factor: 3.396

2.  SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.

Authors:  Klaudia Skrzypek; Anna Kusienicka; Elzbieta Trzyna; Barbara Szewczyk; Aleksandra Ulman; Pawel Konieczny; Tomasz Adamus; Bogna Badyra; Marcin Kortylewski; Marcin Majka
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

3.  Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: A Novel Model for Studies of Its Role.

Authors:  Aleksandra Ulman; Klaudia Skrzypek; Paweł Konieczny; Claudio Mussolino; Toni Cathomen; Marcin Majka
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

4.  Epigenetically upregulated GEFT-derived invasion and metastasis of rhabdomyosarcoma via epithelial mesenchymal transition promoted by the Rac1/Cdc42-PAK signalling pathway.

Authors:  Chunxia Liu; Liang Zhang; Wenwen Cui; Juan Du; Zhenzhen Li; Yuwen Pang; Qianqian Liu; Hao Shang; Lian Meng; Wanyu Li; Lingxie Song; Ping Wang; Yuwen Xie; Yuanyuan Wang; Yang Liu; Jianming Hu; Wenjie Zhang; Feng Li
Journal:  EBioMedicine       Date:  2019-11-21       Impact factor: 8.143

Review 5.  Non-coding RNA in rhabdomyosarcoma progression and metastasis.

Authors:  Farah Ramadan; Raya Saab; Nader Hussein; Philippe Clézardin; Pascale A Cohen; Sandra E Ghayad
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

6.  Enhancement of myogenic differentiation and inhibition of rhabdomyosarcoma progression by miR-28-3p and miR-193a-5p regulated by SNAIL.

Authors:  Klaudia Skrzypek; Artur Nieszporek; Bogna Badyra; Małgorzata Lasota; Marcin Majka
Journal:  Mol Ther Nucleic Acids       Date:  2021-04-20       Impact factor: 8.886

7.  Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.

Authors:  Klaudia Skrzypek; Anna Kusienicka; Barbara Szewczyk; Tomasz Adamus; Ewa Lukasiewicz; Katarzyna Miekus; Marcin Majka
Journal:  Oncotarget       Date:  2015-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.